Inmunotek S.L.   Report issue

For profit Phase 2 Phase 3
Founded: Madrid Spain (1992)
Status: No NME R&D (1992)

Organization Overview

First Clinical Trial
2012
NCT01734811
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Inmunotek S.L.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Bacterial Infections (Phase 3)

Bronchial Spasm (Phase 3)

Bronchiolitis (Phase 3)

Bronchitis (Phase 3)

Conjunctivitis (Phase 2)

Hypersensitivity (Phase 2)

Immune System Diseases (Phase 3)

Infections (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pneumonia (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Respiratory Sounds (Phase 3)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 2)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 11